BHC Stock Analysis: Buy, Sell, or Hold?
BHC - Bausch Health Companies Inc
$6.51
0.17 (2.68%)
▲
5d:
+4.16%
30d:
+32.05%
90d:
+19.45%
WAIT
LOW Confidence
Analysis Updated: Aug 14, 2026 12:00 AM ET
Earnings: Jul 29, 2026
0d
Get Alerted When BHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BHC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BHC shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.55
Based on -1.0% avg growth
INTRINSIC VALUE TODAY
$3.45
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BHC is currently trading at $6.51, which is considered extended relative to its 30-day fair value range of $4.53 to $6.22. From a valuation perspective, the stock is trading at a premium (Forward PE: 1.6) compared to its historical average (1.4). At these levels, the market is pricing in 3.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BHC is in a strong uptrend. Immediate support is located at $5.88, while resistance sits at $7.30.
Market Sentiment: BHC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.50 (+15.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BHC is in a strong uptrend. Immediate support is located at $5.88, while resistance sits at $7.30.
Market Sentiment: BHC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.50 (+15.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.53 -
$6.22
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
27.1%
Protect Your Profits
Holding BHC? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($7.50)
- NEUTRAL: Market pricing in 3.6% annual earnings growth - fairly valued
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.53 -
$6.22
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$5.88
Resistance Level
$7.30
Current Trend
Strong Uptrend
Technical data as of
Aug 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.55
Wall Street Target
$7.50
(+15.2%)
Revenue Growth (YoY)
12.7%
Earnings Growth (YoY)
70.4%
Profit Margin
-10.1%
Valuation Premium vs History
+3.6% premium
PE vs Historical
1.6 vs 1.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.6%
(market-implied from PE analysis)
1-Year Target
$6.74
(+4%)
2-Year Target
$6.99
(+7%)
3-Year Target
$7.24
(+11%)
3-Yr Target (if PE normalizes)
(PE: 2→1)
PE COMPRESSION
$6.53
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: -6.1%)
$70.20
(+978%)
Base:
(SPY PE: 1.6, Growth: -6.1%)
$5.39
(-17%)
Bear:
(PE: 1.3, Growth: -6.1%)
$4.58
(-30%)
Share & Embed Analysis
Last updated: August 15, 2026 6:33 PM ET
Data refreshes hourly during market hours. Next update: 7:33 PM
Data refreshes hourly during market hours. Next update: 7:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$213 | 61 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$108 | 44 HOLD |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
ALKS
Alkermes Plc |
BUY
15 analysts |
$56 | 68 BUY |
Advanced BHC Option Strategies
Professional options setups generated by AI based on today's BHC price and gamma walls.
